share_log

424B3: Prospectus

424B3: Prospectus

424B3：募資說明書
美股sec公告 ·  04/23 16:06
Moomoo AI 已提取核心訊息
Adial Pharmaceuticals, Inc. has filed a prospectus related to the resale of up to 2,369,000 shares of common stock by Selling Stockholders. The shares are associated with Series C Common Warrants and Placement Agent Warrants issued in a private placement transaction that closed on March 6, 2024. The Selling Stockholders include certain identified stockholders and designees of H.C. Wainwright & Co., LLC, the placement agent for the private placement. The registration of these shares does not necessarily mean that the Selling Stockholders will sell their stock, as the sale is at their discretion. Adial Pharmaceuticals will not offer any shares under this prospectus and will not receive proceeds from the sale of the shares by the Selling Stockholders. However, the company will receive proceeds from any cash exercise of the warrants. The common stock is listed on the Nasdaq Capital Market under the symbol 'ADIL.' As of April 10, 2024, the closing price of Adial's common stock was $2.33 per share. The date of the prospectus is April 19, 2024.
Adial Pharmaceuticals, Inc. has filed a prospectus related to the resale of up to 2,369,000 shares of common stock by Selling Stockholders. The shares are associated with Series C Common Warrants and Placement Agent Warrants issued in a private placement transaction that closed on March 6, 2024. The Selling Stockholders include certain identified stockholders and designees of H.C. Wainwright & Co., LLC, the placement agent for the private placement. The registration of these shares does not necessarily mean that the Selling Stockholders will sell their stock, as the sale is at their discretion. Adial Pharmaceuticals will not offer any shares under this prospectus and will not receive proceeds from the sale of the shares by the Selling Stockholders. However, the company will receive proceeds from any cash exercise of the warrants. The common stock is listed on the Nasdaq Capital Market under the symbol 'ADIL.' As of April 10, 2024, the closing price of Adial's common stock was $2.33 per share. The date of the prospectus is April 19, 2024.
Adial Pharmicals, Inc.已提交了一份招股說明書，內容涉及賣出股東轉售多達2369,000股普通股。這些股票與在2024年3月6日結束的私募交易中發行的C系列普通認股權證和配售代理認股權證有關。出售股東包括私募配售代理機構H.C. Wainwright & Co., LLC的某些特定股東和指定人。這些股票的註冊並不一定意味着賣出股東將出售其股票，因爲出售由他們自行決定。Adial Pharmicals不會根據本招股說明書發行任何股票，也不會獲得出售股東出售股票的收益。但是，該公司將從認股權證的任何現金行使中獲得收益。普通股在納斯達克資本市場上市，股票代碼爲 “ADIL”。截至2024年4月10日，阿迪亞爾普通股的收盤價爲每股2.33美元。招股說明書的發佈日期爲2024年4月19日。
Adial Pharmicals, Inc.已提交了一份招股說明書，內容涉及賣出股東轉售多達2369,000股普通股。這些股票與在2024年3月6日結束的私募交易中發行的C系列普通認股權證和配售代理認股權證有關。出售股東包括私募配售代理機構H.C. Wainwright & Co., LLC的某些特定股東和指定人。這些股票的註冊並不一定意味着賣出股東將出售其股票，因爲出售由他們自行決定。Adial Pharmicals不會根據本招股說明書發行任何股票，也不會獲得出售股東出售股票的收益。但是，該公司將從認股權證的任何現金行使中獲得收益。普通股在納斯達克資本市場上市，股票代碼爲 “ADIL”。截至2024年4月10日，阿迪亞爾普通股的收盤價爲每股2.33美元。招股說明書的發佈日期爲2024年4月19日。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息